European Union -
English -
EMA (European Medicines Agency)
viracept
roche registration ltd. - nelfinavir - hiv infections - antivirals for systemic use - viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (hiv-1)-infected adults, adolescents and children of three years of age and older.in protease-inhibitor (pi)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.
Canada -
English -
Health Canada
viracept -250mg tablet
pfizer canada ulc - nelfinavir (nelfinavir mesylate) - tablet - 250mg - nelfinavir (nelfinavir mesylate) 250mg - hiv protease inhibitors
Canada -
English -
Health Canada
viracept -50mg powder
pfizer canada ulc - nelfinavir (nelfinavir mesylate) - powder - 50mg - nelfinavir (nelfinavir mesylate) 50mg - hiv protease inhibitors
Canada -
English -
Health Canada
viracept tablet
pfizer canada ulc - nelfinavir (nelfinavir mesylate) - tablet - 625mg - nelfinavir (nelfinavir mesylate) 625mg - hiv protease inhibitors
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
viracept 250mg tablets
roche products ltd - nelfinavir mesilate - tablet - 250mg
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
viracept 50mgg oral powder
roche products ltd - nelfinavir mesilate - powder - 50mg/1gram